Assessing the Benefits of Drug Delivery by Nanocarriers: A Partico/Pharmacokinetic Framework

Objective: An in vivo kinetic framework is introduced to analyze and predict the quantitative advantage of using nanocarriers to deliver drugs, especially anticancer agents, compared to administering the same drugs in their free form. Methods: This framework recognizes three levels of kinetics. First is the particokinetics associated with deposition of nanocarriers into tissues associated with drug effect and toxicity, their residence inside those tissues, and elimination of the nanocarriers from the body. Second is the release pattern in time of free drug from the nanocarriers. Third is the pharmacokinetics of free drug, as it relates to deposition and elimination processes in the target and toxicity associated tissues, and total body clearance. A figure of merit, the drug targeting index (DTI), is used to quantitate the benefit of nanocarrier-based drug delivery by considering the effects of preferential deposition of nanoparticles into target tissues and relative avoidance of tissues associated with drug toxicity, compared to drug that is administered in its free form. Results: General methods are derived for calculating DTI when appropriate particokinetic, pharmacokinetic, and drug release rate information is available, and it is shown that relatively simple algebraic forms result when some common assumptions are made. Conclusion: This approach may find use in developing and selecting nanocarrier formulations, either for populations or for individuals.

[1]  S. Moghimi,et al.  Just so stories: the random acts of anti-cancer nanomedicine performance. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[2]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[3]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[4]  Y. Bae,et al.  Self-Assembled Hydrogel Nanoparticles Responsive to Tumor Extracellular pH from Pullulan Derivative/Sulfonamide Conjugate: Characterization, Aggregation, and Adriamycin Release in Vitro , 2002, Pharmaceutical Research.

[5]  Omid C. Farokhzad,et al.  Nanoparticle-Aptamer Bioconjugates , 2004, Cancer Research.

[6]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[7]  Y. Tseng,et al.  Phase I and pharmacokinetic study of a stable, polyethylene‐glycolated liposomal doxorubicin in patients with solid tumors , 2001, Cancer.

[8]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[9]  Jayanth Panyam,et al.  Biodegradable nanoparticles for drug and gene delivery to cells and tissue. , 2003, Advanced drug delivery reviews.

[10]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[11]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[12]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[13]  Atsushi Harada,et al.  Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. , 2003, Angewandte Chemie.

[14]  Ronald A. Siegel,et al.  Comparison and critique of two models for regional drug delivery , 1991, Journal of Pharmacokinetics and Biopharmaceutics.

[15]  L. Huang,et al.  Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes. , 1992, Biochimica et biophysica acta.

[16]  D. Christensen,et al.  Ultrasound-triggered drug targeting of tumors in vitro and in vivo. , 2004, Ultrasonics.

[17]  R. Jain,et al.  Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. , 2013, Cancer research.

[18]  Spring Berman,et al.  A computational framework for identifying design guidelines to increase the penetration of targeted nanoparticles into tumors. , 2013, Nano today.

[19]  Jianghong Fan,et al.  Physiologically Based Pharmacokinetic Modeling of Nanoparticles. , 2019, Journal of pharmaceutical sciences.

[20]  Xin Yu Wang,et al.  Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[21]  Guangjun Nie,et al.  Understanding the particokinetics of engineered nanomaterials for safe and effective therapeutic applications. , 2013, Small.

[22]  C. Brazel.  Magnetothermally-responsive Nanomaterials: Combining Magnetic Nanostructures and Thermally-Sensitive Polymers for Triggered Drug Release , 2009, Pharmaceutical Research.

[23]  Jun Wang,et al.  Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. , 2016, ACS nano.

[24]  S. Pun,et al.  Increased nanoparticle penetration in collagenase-treated multicellular spheroids , 2007, International journal of nanomedicine.

[25]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[26]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[27]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[28]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[29]  J. Vallner.  Binding of drugs by albumin and plasma protein. , 1977, Journal of pharmaceutical sciences.

[30]  Donald E Mager,et al.  Systems Pharmacological Analysis of Paclitaxel-Mediated Tumor Priming That Enhances Nanocarrier Deposition and Efficacy , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[31]  Alexander L. Klibanov,et al.  Microbubbles in ultrasound-triggered drug and gene delivery. , 2008, Advanced drug delivery reviews.

[32]  X. Qu,et al.  Near‐Infrared Light‐Triggered, Targeted Drug Delivery to Cancer Cells by Aptamer Gated Nanovehicles , 2012, Advanced materials.

[33]  Ameya R. Kirtane,et al.  A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine. , 2015, Journal of pharmaceutical sciences.

[34]  James M. Gallo,et al.  The Pharmacokinetic/Pharmacodynamic Pipeline: Translating Anticancer Drug Pharmacology to the Clinic , 2011, The AAPS Journal.

[35]  Jinwoo Cheon,et al.  On-demand drug release system for in vivo cancer treatment through self-assembled magnetic nanoparticles. , 2013, Angewandte Chemie.

[36]  Leaf Huang,et al.  Pharmacokinetics and biodistribution of nanoparticles. , 2008, Molecular pharmaceutics.

[37]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[38]  C. Anthony Hunt,et al.  Engineering Targeted In Vivo Drug Delivery. I. The Physiological and Physicochemical Principles Governing Opportunities and Limitations , 1986, Pharmaceutical Research.

[39]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[40]  Paolo P. Provenzano,et al.  Interstitial Pressure in Pancreatic Ductal Adenocarcinoma Is Dominated by a Gel-Fluid Phase. , 2016, Biophysical journal.

[41]  D. Hallahan,et al.  Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. , 2006, Nano letters.

[42]  Gang Zheng,et al.  Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. , 2014, ACS nano.

[43]  Triantafyllos Stylianopoulos,et al.  Combining two strategies to improve perfusion and drug delivery in solid tumors , 2013, Proceedings of the National Academy of Sciences.

[44]  Wah Chiu,et al.  Remotely triggered liposome release by near-infrared light absorption via hollow gold nanoshells. , 2008, Journal of the American Chemical Society.

[45]  Kinam Park,et al.  Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Gang Zheng,et al.  Tailoring nanoparticle designs to target cancer based on tumor pathophysiology , 2016, Proceedings of the National Academy of Sciences.

[47]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[48]  Jennifer I. Hare,et al.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. , 2017, Advanced drug delivery reviews.

[49]  K Dane Wittrup,et al.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. , 2008, Advanced drug delivery reviews.

[50]  Yang Liu,et al.  Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. , 2014, Biomaterials.

[51]  Ameya R. Kirtane,et al.  Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities. , 2013, Advanced drug delivery reviews.

[52]  Kazunori Kataoka,et al.  Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.

[53]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[54]  S. Wise.  Nanocarriers as an emerging platform for cancer therapy , 2007 .

[55]  N. Lassen,et al.  Tracer kinetic methods in medical physiology , 1979 .

[56]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.